Symbols / TMDX Stock $113.21 -1.26% TransMedics Group, Inc.
TMDX (Stock) Chart
About
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Stock Fundamentals
Scroll to Statements| Market Cap | 3.91B | Enterprise Value | 3.91B | Income | 190.29M | Sales | 605.49M | Book/sh | 13.81 | Cash/sh | 14.24 |
| Dividend Yield | — | Payout | 0.00% | Employees | 898 | IPO | — | P/E | 23.25 | Forward P/E | 30.74 |
| PEG | — | P/S | 6.46 | P/B | 8.20 | P/C | — | EV/EBITDA | 29.11 | EV/Sales | 6.46 |
| Quick Ratio | 6.41 | Current Ratio | 7.14 | Debt/Eq | 109.76 | LT Debt/Eq | — | EPS (ttm) | 4.87 | EPS next Y | 3.68 |
| EPS Growth | 11.88% | Revenue Growth | 32.20% | Earnings | 2026-05-05 | ROA | 7.25% | ROE | 54.24% | ROIC | — |
| Gross Margin | 59.92% | Oper. Margin | 13.23% | Profit Margin | 31.43% | Shs Outstand | 34.54M | Shs Float | 33.19M | Short Float | 36.27% |
| Short Ratio | 7.66 | Short Interest | — | 52W High | 156.00 | 52W Low | 88.50 | Beta | 2.08 | Avg Volume | 891.12K |
| Volume | 880.00K | Target Price | $155.00 | Recom | Buy | Prev Close | $114.65 | Price | $113.21 | Change | -1.26% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-06 | main | Evercore ISI Group | Outperform → Outperform | $118 |
| 2026-03-09 | main | Stifel | Hold → Hold | $130 |
| 2026-02-25 | main | JP Morgan | Neutral → Neutral | $149 |
| 2026-02-25 | main | Oppenheimer | Outperform → Outperform | $175 |
| 2026-02-25 | main | Piper Sandler | Overweight → Overweight | $160 |
| 2026-02-25 | main | Evercore ISI Group | Outperform → Outperform | $170 |
| 2026-02-25 | main | Needham | Buy → Buy | $174 |
| 2025-12-17 | main | Canaccord Genuity | Buy → Buy | $148 |
| 2025-12-08 | main | Needham | Buy → Buy | $166 |
| 2025-12-02 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $135 |
| 2025-10-30 | main | Canaccord Genuity | Buy → Buy | $147 |
| 2025-10-30 | main | Piper Sandler | Overweight → Overweight | $140 |
| 2025-10-23 | up | Needham | Hold → Buy | $148 |
| 2025-10-14 | main | Canaccord Genuity | Buy → Buy | $142 |
| 2025-10-13 | init | Jefferies | — → Buy | $145 |
| 2025-09-16 | init | Evercore ISI Group | — → Outperform | $155 |
| 2025-09-04 | init | Stifel | — → Hold | $115 |
| 2025-08-25 | reit | Needham | Hold → Hold | — |
| 2025-08-01 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $123 |
| 2025-07-15 | main | Canaccord Genuity | Buy → Buy | $142 |
- (TMDX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily Fri, 24 Apr 2026 00
- Is TransMedics Group, Inc. (TMDX) A Good Stock To Buy Now? - Yahoo Finance Sun, 15 Mar 2026 07
- TransMedics puts new organ-cooling device into heart, lung trial plans - Stock Titan hu, 23 Apr 2026 11
- TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026 - ChartMill ue, 21 Apr 2026 20
- A Look at TransMedics Group Inc (TMDX) After 5.3% Gain -- GF Val - GuruFocus Wed, 22 Apr 2026 23
- $TMDX stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Wed, 18 Mar 2026 07
- Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Boston Scientific (BSX) - The Globe and Mail hu, 23 Apr 2026 09
- TransMedics Group (NASDAQ:TMDX) Stock Price Up 8.5% - Here's What Happened - MarketBeat Fri, 17 Apr 2026 18
- Up 95% In Last 12 Months, Can TransMedics Stock Keep Climbing In 2026? - TIKR.com Wed, 04 Feb 2026 08
- TransMedics: Rapidly Scaling Business Nears Free Cash Flow Breakeven (NASDAQ:TMDX) - Seeking Alpha Mon, 16 Mar 2026 07
- TransMedics (TMDX) Down 20.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance hu, 26 Mar 2026 07
- TransMedics will discuss first-quarter results after market close May 5 - Stock Titan ue, 21 Apr 2026 20
- Reasons to Retain TransMedics Stock in Your Portfolio for Now - Yahoo Finance Wed, 25 Mar 2026 07
- TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates - Yahoo Finance Wed, 25 Feb 2026 08
- Assessing TransMedics Group (TMDX) Valuation After Recent Short Term Share Price Weakness - Yahoo Finance Sun, 08 Mar 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
605.49
+37.13%
|
441.54
+82.74%
|
241.62
+158.53%
|
93.46
|
| Operating Revenue |
|
605.49
+37.19%
|
441.35
+82.68%
|
241.60
+162.38%
|
92.08
|
| Cost Of Revenue |
|
242.69
+35.23%
|
179.46
+105.03%
|
87.53
+210.53%
|
28.19
|
| Reconciled Cost Of Revenue |
|
242.69
+35.23%
|
179.46
+105.03%
|
87.53
+210.53%
|
28.19
|
| Gross Profit |
|
362.81
+38.43%
|
262.08
+70.08%
|
154.09
+136.08%
|
65.27
|
| Operating Expense |
|
254.22
+13.20%
|
224.59
+22.84%
|
182.82
+89.04%
|
96.71
|
| Research And Development |
|
69.06
+23.38%
|
55.97
-11.54%
|
63.27
+135.97%
|
26.81
|
| Selling General And Administration |
|
185.17
+9.82%
|
168.62
+41.04%
|
119.55
+71.04%
|
69.90
|
| Selling And Marketing Expense |
|
4.32
|
—
|
—
|
18.21
|
| General And Administrative Expense |
|
180.85
+7.26%
|
168.62
+41.04%
|
119.55
+131.30%
|
51.69
|
| Salaries And Wages |
|
114.51
+4.60%
|
109.47
+50.55%
|
72.72
+84.80%
|
39.35
|
| Other Gand A |
|
66.35
+12.18%
|
59.14
+26.27%
|
46.84
+279.61%
|
12.34
|
| Total Expenses |
|
496.91
+22.98%
|
404.04
+49.45%
|
270.35
+116.46%
|
124.90
|
| Operating Income |
|
108.58
+189.59%
|
37.50
+230.53%
|
-28.73
+8.62%
|
-31.44
|
| Total Operating Income As Reported |
|
108.58
+189.59%
|
37.50
+230.53%
|
-28.73
+8.62%
|
-31.44
|
| EBITDA |
|
148.49
+112.29%
|
69.95
+1008.05%
|
-7.70
+73.40%
|
-28.96
|
| Normalized EBITDA |
|
148.49
+112.29%
|
69.95
+1008.05%
|
-7.70
+73.40%
|
-28.96
|
| Reconciled Depreciation |
|
27.18
+37.59%
|
19.76
+141.63%
|
8.18
+135.11%
|
3.48
|
| EBIT |
|
121.30
+141.69%
|
50.19
+416.05%
|
-15.88
+51.05%
|
-32.44
|
| Total Unusual Items |
|
—
|
—
|
0.30
+115.79%
|
-1.90
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.30
+115.79%
|
-1.90
|
| Special Income Charges |
|
—
|
—
|
-27.21
-4435.33%
|
-0.60
|
| Other Special Charges |
|
—
|
—
|
27.21
+4435.33%
|
0.60
|
| Net Income |
|
190.29
+436.58%
|
35.46
+241.70%
|
-25.03
+30.92%
|
-36.23
|
| Pretax Income |
|
107.52
+200.51%
|
35.78
+234.15%
|
-26.67
+26.25%
|
-36.16
|
| Net Non Operating Interest Income Expense |
|
-13.78
+4.35%
|
-14.41
-33.53%
|
-10.79
-189.61%
|
-3.73
|
| Interest Expense Non Operating |
|
13.78
-4.35%
|
14.41
+33.53%
|
10.79
+189.61%
|
3.73
|
| Net Interest Income |
|
-13.78
+4.35%
|
-14.41
-33.53%
|
-10.79
-189.61%
|
-3.73
|
| Interest Expense |
|
13.78
-4.35%
|
14.41
+33.53%
|
10.79
+189.61%
|
3.73
|
| Interest Income Non Operating |
|
—
|
—
|
12.50
+1288.89%
|
0.90
|
| Interest Income |
|
—
|
—
|
12.50
+1288.89%
|
0.90
|
| Other Income Expense |
|
12.72
+0.22%
|
12.69
-1.20%
|
12.85
+1382.14%
|
-1.00
|
| Other Non Operating Income Expenses |
|
12.72
+0.22%
|
12.69
-1.20%
|
12.85
+1382.14%
|
-1.00
|
| Gain On Sale Of Security |
|
—
|
—
|
0.30
+123.08%
|
-1.30
|
| Tax Provision |
|
-82.77
-26292.72%
|
0.32
+119.23%
|
-1.64
-2589.39%
|
0.07
|
| Tax Rate For Calcs |
|
0.00
+2233.33%
|
0.00
-85.48%
|
0.00
-70.48%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
190.29
+436.58%
|
35.46
+241.70%
|
-25.03
+30.92%
|
-36.23
|
| Net Income From Continuing Operation Net Minority Interest |
|
190.29
+436.58%
|
35.46
+241.70%
|
-25.03
+30.92%
|
-36.23
|
| Net Income From Continuing And Discontinued Operation |
|
190.29
+436.58%
|
35.46
+241.70%
|
-25.03
+30.92%
|
-36.23
|
| Net Income Continuous Operations |
|
190.29
+436.58%
|
35.46
+241.70%
|
-25.03
+30.92%
|
-36.23
|
| Normalized Income |
|
190.29
+436.58%
|
35.46
+241.70%
|
-25.03
+30.92%
|
-36.23
|
| Net Income Common Stockholders |
|
190.29
+436.58%
|
35.46
+241.70%
|
-25.03
+30.92%
|
-36.23
|
| Diluted EPS |
|
4.87
+382.18%
|
1.01
+231.17%
|
-0.77
+37.40%
|
-1.23
|
| Basic EPS |
|
5.60
+423.36%
|
1.07
+238.96%
|
-0.77
+37.40%
|
-1.23
|
| Basic Average Shares |
|
33.99
+2.30%
|
33.23
+2.19%
|
32.52
+10.02%
|
29.56
|
| Diluted Average Shares |
|
40.54
+15.12%
|
35.22
+8.30%
|
32.52
+10.02%
|
29.56
|
| Diluted NI Availto Com Stockholders |
|
190.29
+436.58%
|
35.46
+241.70%
|
-25.03
+30.92%
|
-36.23
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
706.05
|
| Current Assets |
|
510.65
|
| Cash Cash Equivalents And Short Term Investments |
|
394.81
|
| Cash And Cash Equivalents |
|
394.81
|
| Cash Financial |
|
394.81
|
| Other Short Term Investments |
|
—
|
| Receivables |
|
63.58
|
| Accounts Receivable |
|
63.58
|
| Inventory |
|
44.23
|
| Raw Materials |
|
25.82
|
| Work In Process |
|
3.81
|
| Finished Goods |
|
14.61
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
8.03
|
| Total Non Current Assets |
|
195.39
|
| Net PPE |
|
180.49
|
| Gross PPE |
|
201.78
|
| Accumulated Depreciation |
|
-21.29
|
| Properties |
|
0.00
|
| Land And Improvements |
|
—
|
| Machinery Furniture Equipment |
|
152.37
|
| Construction In Progress |
|
6.25
|
| Other Properties |
|
29.81
|
| Leases |
|
13.35
|
| Goodwill And Other Intangible Assets |
|
14.34
|
| Goodwill |
|
11.99
|
| Other Intangible Assets |
|
2.35
|
| Non Current Deferred Assets |
|
—
|
| Non Current Deferred Taxes Assets |
|
—
|
| Other Non Current Assets |
|
0.56
|
| Total Liabilities Net Minority Interest |
|
568.85
|
| Current Liabilities |
|
54.93
|
| Payables And Accrued Expenses |
|
50.94
|
| Payables |
|
12.72
|
| Accounts Payable |
|
12.72
|
| Current Accrued Expenses |
|
38.22
|
| Current Debt And Capital Lease Obligation |
|
2.04
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
2.04
|
| Current Deferred Liabilities |
|
1.96
|
| Current Deferred Revenue |
|
1.96
|
| Total Non Current Liabilities Net Minority Interest |
|
513.91
|
| Long Term Debt And Capital Lease Obligation |
|
513.91
|
| Long Term Debt |
|
506.20
|
| Long Term Capital Lease Obligation |
|
7.71
|
| Non Current Deferred Liabilities |
|
—
|
| Stockholders Equity |
|
137.20
|
| Common Stock Equity |
|
137.20
|
| Capital Stock |
|
641.11
|
| Common Stock |
|
641.11
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
32.67
|
| Ordinary Shares Number |
|
32.67
|
| Treasury Shares Number |
|
0.00
|
| Retained Earnings |
|
-503.70
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.20
|
| Other Equity Adjustments |
|
-0.20
|
| Total Equity Gross Minority Interest |
|
137.20
|
| Total Capitalization |
|
643.41
|
| Working Capital |
|
455.72
|
| Invested Capital |
|
643.41
|
| Total Debt |
|
515.95
|
| Net Debt |
|
111.39
|
| Capital Lease Obligations |
|
9.74
|
| Net Tangible Assets |
|
122.86
|
| Tangible Book Value |
|
122.86
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
192.84
+295.14%
|
48.80
+474.60%
|
-13.03
+71.57%
|
-45.82
|
| Cash Flow From Continuing Operating Activities |
|
192.84
+295.14%
|
48.80
+474.60%
|
-13.03
+71.57%
|
-45.82
|
| Net Income From Continuing Operations |
|
190.29
+436.58%
|
35.46
+241.70%
|
-25.03
+30.92%
|
-36.23
|
| Depreciation Amortization Depletion |
|
27.18
+37.59%
|
19.76
+141.63%
|
8.18
+135.11%
|
3.48
|
| Depreciation And Amortization |
|
27.18
+37.59%
|
19.76
+141.63%
|
8.18
+135.11%
|
3.48
|
| Other Non Cash Items |
|
5.21
+11.49%
|
4.67
-84.61%
|
30.38
+2470.30%
|
1.18
|
| Stock Based Compensation |
|
36.86
+10.95%
|
33.22
+67.87%
|
19.79
+91.75%
|
10.32
|
| Deferred Tax |
|
-83.54
|
0.00
+100.00%
|
-1.66
|
0.00
|
| Deferred Income Tax |
|
-83.54
|
0.00
+100.00%
|
-1.66
|
0.00
|
| Operating Gains Losses |
|
-1.54
-326.10%
|
0.68
+299.42%
|
-0.34
-118.88%
|
1.81
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
0.11
|
| Net Foreign Currency Exchange Gain Loss |
|
-1.62
-343.91%
|
0.67
+294.44%
|
-0.34
-130.29%
|
1.13
|
| Gain Loss On Sale Of PPE |
|
0.08
+370.59%
|
0.02
|
0.00
|
0.00
|
| Change In Working Capital |
|
18.38
+140.84%
|
-45.00
-1.47%
|
-44.35
-65.73%
|
-26.76
|
| Change In Receivables |
|
13.95
+140.66%
|
-34.31
-1.46%
|
-33.82
-55.99%
|
-21.68
|
| Changes In Account Receivables |
|
13.95
+140.66%
|
-34.31
-1.46%
|
-33.82
-55.99%
|
-21.68
|
| Change In Inventory |
|
-7.72
+7.63%
|
-8.35
+70.27%
|
-28.09
-250.10%
|
-8.02
|
| Change In Prepaid Assets |
|
-3.76
+39.97%
|
-6.26
-198.05%
|
-2.10
-183.34%
|
2.52
|
| Change In Payables And Accrued Expense |
|
17.68
+170.18%
|
6.54
-69.15%
|
21.21
+12598.80%
|
0.17
|
| Change In Accrued Expense |
|
17.69
+122.90%
|
7.94
-44.29%
|
14.25
+314.61%
|
3.44
|
| Change In Payable |
|
-0.02
+98.64%
|
-1.40
-120.07%
|
6.96
+312.75%
|
-3.27
|
| Change In Account Payable |
|
-0.02
+98.64%
|
-1.40
-120.07%
|
6.96
+312.75%
|
-3.27
|
| Change In Other Working Capital |
|
1.14
+663.55%
|
-0.20
-344.58%
|
0.08
|
—
|
| Change In Other Current Assets |
|
-0.02
+84.56%
|
-0.15
-175.93%
|
-0.05
|
0.00
|
| Change In Other Current Liabilities |
|
-2.90
-27.81%
|
-2.27
-43.90%
|
-1.57
-717.25%
|
0.26
|
| Investing Cash Flow |
|
-59.25
+54.18%
|
-129.30
+33.33%
|
-193.95
-455.79%
|
54.51
|
| Cash Flow From Continuing Investing Activities |
|
-59.25
+54.18%
|
-129.30
+33.33%
|
-193.95
-455.79%
|
54.51
|
| Net PPE Purchase And Sale |
|
-59.25
+54.33%
|
-129.74
+14.56%
|
-151.85
-1175.28%
|
-11.91
|
| Purchase Of PPE |
|
-59.25
+54.33%
|
-129.74
+14.56%
|
-151.85
-1175.28%
|
-11.91
|
| Capital Expenditure |
|
-59.25
+54.33%
|
-129.74
+27.54%
|
-179.06
-1403.81%
|
-11.91
|
| Net Investment Purchase And Sale |
|
—
|
0.00
|
0.00
-100.00%
|
66.42
|
| Purchase Of Investment |
|
—
|
0.00
|
0.00
+100.00%
|
-10.50
|
| Sale Of Investment |
|
—
|
0.00
|
0.00
-100.00%
|
76.92
|
| Net Business Purchase And Sale |
|
0.00
-100.00%
|
0.44
+102.96%
|
-14.89
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
-14.89
|
0.00
|
| Net Intangibles Purchase And Sale |
|
0.00
|
0.00
+100.00%
|
-27.21
|
0.00
|
| Purchase Of Intangibles |
|
0.00
|
0.00
+100.00%
|
-27.21
|
0.00
|
| Financing Cash Flow |
|
16.86
-26.30%
|
22.87
-94.29%
|
400.42
+138.45%
|
167.93
|
| Cash Flow From Continuing Financing Activities |
|
16.86
-26.30%
|
22.87
-94.29%
|
400.42
+138.45%
|
167.93
|
| Net Issuance Payments Of Debt |
|
0.00
|
0.00
-100.00%
|
445.38
+1883.08%
|
22.46
|
| Issuance Of Debt |
|
0.00
|
0.00
-100.00%
|
445.38
+661.22%
|
58.51
|
| Repayment Of Debt |
|
—
|
0.00
|
0.00
+100.00%
|
-36.05
|
| Long Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
445.38
+661.22%
|
58.51
|
| Long Term Debt Payments |
|
—
|
0.00
|
0.00
+100.00%
|
-36.05
|
| Net Long Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
445.38
+1883.08%
|
22.46
|
| Net Common Stock Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
139.85
|
| Proceeds From Stock Option Exercised |
|
17.00
-25.70%
|
22.87
+221.72%
|
7.11
+26.65%
|
5.61
|
| Net Other Financing Charges |
|
-0.14
|
—
|
-52.07
|
—
|
| Changes In Cash |
|
150.45
+361.07%
|
-57.63
-129.79%
|
193.44
+9.52%
|
176.62
|
| Effect Of Exchange Rate Changes |
|
1.27
+336.94%
|
-0.54
-377.72%
|
0.19
+118.90%
|
-1.02
|
| Beginning Cash Position |
|
337.15
-14.71%
|
395.31
+96.01%
|
201.68
+673.32%
|
26.08
|
| End Cash Position |
|
488.87
+45.00%
|
337.15
-14.71%
|
395.31
+96.01%
|
201.68
|
| Free Cash Flow |
|
133.59
+265.04%
|
-80.94
+57.86%
|
-192.09
-232.77%
|
-57.72
|
| Interest Paid Supplemental Data |
|
10.70
-5.27%
|
11.30
+39.66%
|
8.09
+148.13%
|
3.26
|
| Amortization Of Securities |
|
—
|
0.00
|
0.00
-100.00%
|
0.38
|
| Common Stock Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
139.85
|
| Issuance Of Capital Stock |
|
—
|
0.00
|
0.00
-100.00%
|
139.85
|
| Sale Of Business |
|
0.00
-100.00%
|
0.44
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-06 View
- 42026-03-06 View
- 42026-03-04 View
- 42026-03-04 View
- 42026-03-04 View
- 8-K2026-02-27 View
- 10-K2026-02-24 View
- 8-K2026-02-24 View
- 42026-02-20 View
- 8-K2026-02-04 View
- 8-K2026-01-12 View
- 42025-12-05 View
- 42025-12-05 View
- 42025-11-26 View
- 42025-11-18 View
- 42025-10-31 View
- 10-Q2025-10-29 View
- 8-K2025-10-29 View
- 8-K2025-10-06 View
- 42025-08-08 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|